## Figure S4: Effects of statin therapy on CANCER MORTALITY, by baseline LDL cholesterol

| Baseline LDL−C, mmol/L | Events (% py) Statin/more | Events (% py) Control/less | RR (CI) | Trend test |
|---|---|---|---|---|
| **22 Statin vs. control trials (1.08 mmol/L LDL cholesterol difference)** | | | | |
| < 2 | 49 (0.7) | 54 (0.7) | 0.86 (0.51 − 1.42) | $\chi^2_1$=5.02 (p=0.03) |
| ≥ 2,<2.5 | 72 (0.5) | 99 (0.6) | 0.73 (0.49 − 1.09) | |
| ≥ 2.5,<3.0 | 183 (0.5) | 203 (0.6) | 0.89 (0.68 − 1.16) | |
| ≥ 3,<3.5 | 334 (0.6) | 313 (0.6) | 1.06 (0.86 − 1.29) | |
| ≥ 3.5 | 701 (0.4) | 670 (0.4) | 1.04 (0.91 − 1.20) | |
| **Total** | **1365 (0.5)** | **1358 (0.5)** | **1.00 (0.93 − 1.08)** | |
| **5 More vs. less statin trials (0.51 mmol/L LDL cholesterol difference)** | | | | |
| < 2 | 73 (0.4) | 107 (0.6) | 0.68 (0.46 − 1.00) | $\chi^2_1$=2.23 (p=0.14) |
| ≥ 2,<2.5 | 160 (0.5) | 151 (0.5) | 1.04 (0.78 − 1.40) | |
| ≥ 2.5,<3.0 | 127 (0.5) | 139 (0.5) | 0.96 (0.70 − 1.31) | |
| ≥ 3,<3.5 | 49 (0.4) | 39 (0.3) | 1.22 (0.70 − 2.10) | |
| ≥ 3.5 | 35 (0.6) | 38 (0.6) | 0.92 (0.51 − 1.69) | |
| **Total** | **447 (0.5)** | **481 (0.5)** | **0.93 (0.82 − 1.06)** | |
| **All 27 trials** | | | | |
| < 2 | 122 (0.5) | 161 (0.7) | 0.74 (0.55 − 1.01) | $\chi^2_1$=6.99 (p=0.008) |
| ≥ 2,<2.5 | 232 (0.5) | 250 (0.5) | 0.92 (0.73 − 1.16) | |
| ≥ 2.5,<3.0 | 310 (0.5) | 342 (0.6) | 0.92 (0.75 − 1.12) | |
| ≥ 3,<3.5 | 383 (0.6) | 352 (0.5) | 1.07 (0.89 − 1.30) | |
| ≥ 3.5 | 736 (0.5) | 708 (0.4) | 1.04 (0.90 − 1.19) | |
| **Total** | **1812 (0.5)** | **1839 (0.5)** | **0.98 (0.92 − 1.05)** | |